

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10749962	
	Filing Date		2003-12-31	
	First Named Inventor	GOVARDHAN, Chandrika P.		
	Art Unit	1656		
	Examiner Name	Alexander D. Kim		
	Attorney Docket Number	A2039-701210		

U.S.PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

NON-PATENT LITERATURE DOCUMENTS				Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10749962
Filing Date	2003-12-31
First Named Inventor	GOVARDHAN, Chandrika P.
Art Unit	1656
Examiner Name	Alexander D. Kim
Attorney Docket Number	A2039-701210

1	BRADER et al., "Hypride Insulin Cocystals for Controlled Release Delivery", Nature Biotechnology, vol. 20, no. 8, pp 800-804, August 2002.	<input type="checkbox"/>
2	JEN et al., "Diamonds in the Rough: Protein Crystals from a Formulation Perspective", Pharmaceutical Research, vol. 18, no. 11 pp. 1483-1488, November 2001	<input type="checkbox"/>
3	MAA Y-F et al., "Spray-Drying of Air-Liquid Interface Sensitive Recombinant Human Growth Hormone", Journal of Pharmaceutical Science, vol. 87, no. 2, pp 152-159, February 1998.	<input type="checkbox"/>
4	CLELAND J L et al., "Stable Formulations of Recombinant Human Growth Hormone and Interferon-Gamma for Microencapsulation in Biodegradable Microspheres", Pharmaceutical Research, vol. 13, no. 10 pp 1464-1475, January 1996.	<input type="checkbox"/>
5	GOVARDHAN Chandrika et al., Novel Long-Acting Crystal Formulation of Human Growth Hormone", Pharmaceutical Research, vol. 22, no. 9, pp 1461-1470, September 2005.	<input type="checkbox"/>
6	Supplementary European Search Report from corresponding EP Application No.: 03808602.1 dated February 3, 2009.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.